Provention Bio, Inc. (PRVB)
| Market Cap | 393.56M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -125.46M |
| Shares Out | 63.38M |
| EPS (ttm) | -2.10 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 35,809 |
| Open | 6.18 |
| Previous Close | 6.21 |
| Day's Range | 6.11 - 6.23 |
| 52-Week Range | 5.59 - 20.05 |
| Beta | 2.96 |
| Analysts | Buy |
| Price Target | 15.64 (+156.0%) |
| Est. Earnings Date | Nov 4, 2021 |
About PRVB
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-6527, an oral CSF-1R inhibitor, which has completed Phase IIa clinical trial for the treatment of Crohn's disease; PRV-3279, which has completed Phase Ib clinical trial for the treat...
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for Provention Bio stock is "Buy." The 12-month stock price forecast is 15.64, which is an increase of 155.97% from the latest price.
News
Provention Bio to Present at the Cantor Fitzgerald Virtual Global Healthcare Conference 2021
RED BANK, N.J., Sept. 23, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that man...
Provention Bio to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
RED BANK, N.J., Sept. 16, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that man...
Provention Bio Provides Update on the Potential Timing of Teplizumab At-Risk Type 1 Diabetes (T1D) Biologics License ...
RED BANK, N.J., Sept. 13, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today provided an update...
Provention Bio, Inc. (PRVB) Reports Q2 Loss, Lags Revenue Estimates
Provention Bio, Inc. (PRVB) delivered earnings and revenue surprises of 9.80% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Provention Bio Reports Second Quarter 2021 Financial Results and Provides Business Update
RED BANK, N.J., Aug. 5, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today reported financial r...
Provention Bio to Report Second Quarter 2021 Financial Results on August 5, 2021
RED BANK, N.J., July 29, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it w...
PRVB Final Deadline Today: Rosen, Trusted Investor Counsel, Encourages Provention Bio, Inc. Investors to Secure Couns...
New York, New York--(Newsfile Corp. - July 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between Novembe...
DEADLINE TODAY: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and Enco...
Los Angeles, California--(Newsfile Corp. - July 20, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. (...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and ...
New York, New York--(Newsfile Corp. - July 19, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Pro...
PRVB Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Provention Bio, Inc. Investors of Class Action and Le...
NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Compa...
PRVB TUESDAY DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Provention Bio, Inc. Investors to Secure Counsel B...
New York, New York--(Newsfile Corp. - July 19, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between Novemb...
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc. and E...
Los Angeles, California--(Newsfile Corp. - July 19, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. (...
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Provention Bio, Inc. of...
NEW YORK, July 18, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Provention Bio, Inc. ("Provention" or the "Company")(NASDAQ: PRVB) and certain of its o...
FINAL DEADLINE: ROSEN, A RANKED AND LEADING FIRM, Encourages Provention Bio, Inc. Investors to Secure Counsel Before ...
NEW YORK, July 16, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between November 2, 2020 and A...
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and a L...
New York, New York--(Newsfile Corp. - July 16, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRV...
PRVB LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving Provention Bio, Inc.
New York, New York--(Newsfile Corp. - July 16, 2021) - The Law Offices of Vincent Wong announce that a class action lawsuit has commenced in the on behalf of investors who purchased Provention Bio, Inc....
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention...
LOS ANGELES--(BUSINESS WIRE)---- $PRVB #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio, Inc. (PRVB)
TUESDAY DEADLINE NOTICE: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, Inc....
Los Angeles, California--(Newsfile Corp. - July 16, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. (...
Is Provention Bio a Bad News Buy?
There's a good case this biotech stock is now at least somewhat undervalued.
PRVB ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of July 20, 2021 in the Class Action Filed on Beha...
New York, New York--(Newsfile Corp. - July 15, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Provention Bio, Inc. (NASDAQ: PRVB) allegin...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Provention Bio, Inc. of a Class Action Lawsuit and ...
New York, New York--(Newsfile Corp. - July 15, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Prov...
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Provention Bio,...
LOS ANGELES, July 15, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming July 20, 2021 deadline to file a lead plaintiff motion in the class action filed on beha...
TUESDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Provention Bio, In...
Los Angeles, California--(Newsfile Corp. - July 15, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Provention Bio, Inc. (...
Rosen, Global Investor Counsel, Encourages Provention Bio, Inc. Investors to Secure Counsel Before Important July 20 ...
New York, New York--(Newsfile Corp. - July 14, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Provention Bio, Inc. (NASDAQ: PRVB) between Novembe...